The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback